Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Prospective, Randomized, Pragmatic Open Label Cohort Study to Evaluate the Comparative Effectiveness of Eptinezumab in the United States

NCT05284019 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05284019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05284019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Prospective, Randomized, Pragmatic Open Label Cohort Study to Evaluate the Comparative Effectiveness of Eptinezumab in the United States
Lead sponsor
H. Lundbeck A/S
Phase
Phase 4
Overall status
Terminated
Start date
March 4, 2022
Completion date
April 14, 2023
Enrollment
32 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

migraine